Ophthalmology & Visual Sciences at the Eye Institute

Ophthalmology and Visual Sciences

Currently Enrolling Study

Gilead Uveitis Study for Non-Infectious Uveitis

Purpose of study:
This project is being done to find out whether a new oral drug, filgotinib, reduces the symptoms of non-infectious uveitis, and whether it causes any problems (side effects) in patients with this condition.

What is Non-Infectious Uveitis?
Uveitis is a type of disorder that affects the middle layer of the eye, called the uvea. The non-infectious form of uveitis is not caused by an infection and cannot be spread to others. Different types of uveitis have different causes and can range in severity (from potentially blinding to harmless). This type of uveitis involves inflammation in either the middle or back part of eye, or in the whole eye.

What is involved?

The study will last about 1 year with up to 18 study visits. Study visits will include some imaging of your eyes, a dilated eye exam, a vision test, questionnaires, as well as blood and/or urine tests.
Since we do not know what effect the study drug has on the symptoms of uveitis, participants will have an equal chance of receiving the filgotinib drug or receiving placebo (a pill that looks like the drug, but does not contain any real medication). All subjects will receive an oral corticosteroid over a series of weeks in addition to either the study drug or placebo.

Compensation:
Research volunteers will receive $50 for each study visit that is completed.

You may be eligible to participate in this study if you meet these criteria.

  • You have been told by a doctor that you have uveitis, which it is not caused by an infection.
  • Your uveitis has previously responded well to treatment with oral corticosteroids (like prednisone).
  • You are 18 years or older.
  • You are not pregnant.

More Information:

Additional information about the Gilead Uveitis Study for Non-Infectious Uveitis can be found at ClinicalTrials.gov.

Contact Katie McKenney with questions. (414) 955-7866 or email

IRB Approval: PRO00031648, 6/27/2018